Quadrant Capital Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.13M | Buy |
5,659
+1
| +0% | +$198 | 0.03% | 515 |
|
|
2025
Q4 | $1.07M | Hold |
5,658
| – | – | 0.03% | 520 |
|
|
2025
Q3 | $1M | Hold |
5,658
| – | – | 0.03% | 503 |
|
|
2025
Q2 | $643K | Sell |
5,658
-268
| -5% | -$28.6K | 0.02% | 721 |
|
|
2025
Q1 | $623K | Buy |
5,926
+5,889
| +15,916% | +$666K | 0.02% | 600 |
|
|
2024
Q4 | $3.96K | Hold |
37
| – | – | ﹤0.01% | 2361 |
|
|
2024
Q3 | $3.7K | Hold |
37
| – | – | ﹤0.01% | 2379 |
|
|
2024
Q2 | $3.12K | Hold |
37
| – | – | ﹤0.01% | 2404 |
|
|
2024
Q1 | $2.71K | Hold |
37
| – | – | ﹤0.01% | 2451 |
|
|
2023
Q4 | $2.64K | Sell |
37
-110
| -75% | -$6.49K | ﹤0.01% | 2417 |
|
|
2023
Q3 | $8.81K | Sell |
147
-107
| -42% | -$7.04K | ﹤0.01% | 2023 |
|
|
2023
Q2 | $18.3K | Buy |
254
+7
| +3% | +$525 | ﹤0.01% | 1754 |
|
|
2023
Q1 | $18.2K | Buy |
247
+107
| +76% | +$7.61K | ﹤0.01% | 1746 |
|
|
2022
Q4 | $9.35K | Sell |
140
-105
| -43% | -$6.83K | ﹤0.01% | 1979 |
|
|
2022
Q3 | $13K | Buy |
245
+219
| +842% | +$12.9K | ﹤0.01% | 1768 |
|
|
2022
Q2 | $1K | Buy |
26
+7
| +37% | +$397 | ﹤0.01% | 2392 |
|
|
2022
Q1 | $1K | Hold |
19
| – | – | ﹤0.01% | 2331 |
|
|
2021
Q4 | $2K | Sell |
19
-10
| -34% | -$924 | ﹤0.01% | 2151 |
|
|
2021
Q3 | $3K | Buy |
29
+10
| +53% | +$773 | ﹤0.01% | 2034 |
|
|
2021
Q2 | $2K | Hold |
19
| – | – | ﹤0.01% | 2112 |
|
|
2021
Q1 | $2K | Hold |
19
| – | – | ﹤0.01% | 2082 |
|
|
2020
Q4 | $1K | Buy |
+19
| New | +$1.08K | ﹤0.01% | 2139 |
|
|
2020
Q3 | – | Sell |
-79
| Closed | -$5K | – | 2245 |
|
|
2020
Q2 | $5K | Sell |
79
-851
| -92% | -$53.9K | ﹤0.01% | 1664 |
|
|
2020
Q1 | $42K | Buy |
930
+914
| +5,713% | +$51.8K | 0.01% | 953 |
|
|
2019
Q4 | $0 | Sell |
16
-18
| -53% | -$1.2K | ﹤0.01% | 2456 |
|
|
2019
Q3 | $1K | Sell |
34
-468
| -93% | -$29.4K | ﹤0.01% | 2199 |
|
|
2019
Q2 | $34K | Buy |
502
+468
| +1,376% | +$34.5K | 0.01% | 1379 |
|
|
2019
Q1 | $1K | Sell |
34
-14
| -29% | -$1.06K | ﹤0.01% | 2167 |
|
|
2018
Q4 | $3K | Sell |
48
-21
| -30% | -$2.24K | ﹤0.01% | 1796 |
|
|
2018
Q3 | $10K | Hold |
69
| – | – | ﹤0.01% | 1292 |
|
|
2018
Q2 | $7K | Buy |
69
+21
| +44% | +$2.34K | ﹤0.01% | 1432 |
|
|
2018
Q1 | $4K | Hold |
48
| – | – | ﹤0.01% | 1609 |
|
|
2017
Q4 | $3K | Hold |
48
| – | – | ﹤0.01% | 1660 |
|
|
2017
Q3 | $3K | Buy |
48
+22
| +85% | +$1.74K | ﹤0.01% | 1660 |
|
|
2017
Q2 | $0 | Hold |
26
| – | – | ﹤0.01% | 1961 |
|
|
2017
Q1 | $1K | Hold |
26
| – | – | ﹤0.01% | 1822 |
|
|
2016
Q4 | $1K | Sell |
26
-109
| -81% | -$6.88K | ﹤0.01% | 1727 |
|
|
2016
Q3 | $7K | Hold |
135
| – | – | ﹤0.01% | 1162 |
|
|
2016
Q2 | $9K | Hold |
135
| – | – | 0.01% | 1047 |
|
|
2016
Q1 | $8K | Buy |
+135
| New | +$8.21K | 0.01% | 1038 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Quadrant Capital Group's LGND Position: Q1 2026 in Review
Quadrant Capital Group increased its Ligand Pharmaceuticals (LGND) stake by 0.02% in Q1 2026, buying an estimated $198 and bringing the position to 5,659 shares worth $1.13M. The position accounts for 0.03% of the portfolio, ranked #515.
Quadrant Capital Group first reported a position in LGND in Q1 2016 and has held it in 40 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Quadrant Capital Group held 5,659 shares of Ligand Pharmaceuticals worth $1.13M as of Q1 2026.
- Quadrant Capital Group bought 1 Ligand Pharmaceuticals share in Q1 2026, an estimated $198.
- Ligand Pharmaceuticals made up 0.03% of Quadrant Capital Group's portfolio in Q1 2026, its #515 holding.
- Quadrant Capital Group first reported a position in Ligand Pharmaceuticals in Q1 2016 and has held it in 40 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.